Study of Osimertinib + SRS vs SRS Alone for Brain Metastases in EGFR Positive Patients
about
Study of Osimertinib + SRS vs SRS Alone for Brain Metastases in EGFR Positive Patients
description
clinical trial
@en
klinisch onderzoek
@nl
name
Study of Osimertinib + SRS vs SRS Alone for Brain Metastases in EGFR Positive Patients
@en
type
label
Study of Osimertinib + SRS vs SRS Alone for Brain Metastases in EGFR Positive Patients
@en
prefLabel
Study of Osimertinib + SRS vs SRS Alone for Brain Metastases in EGFR Positive Patients
@en
P1476
Open Label, Multicenter, Phase ...... imertinib or Osimertinib Alone
@en
P3098
NCT03769103
P4844
P580
2019-03-01T00:00:00Z
P582
2022-12-01T00:00:00Z